Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-27T05:18:50.433Z Has data issue: false hasContentIssue false
  • English
  • Français

P0161 - A double-blind, placebo-controlled study with acute and continuation phase of Quetiapine and Paroxetine in adults with bipolar depression (Embolden II)

Published online by Cambridge University Press:  16 April 2020

S. McElroy ,
A.H. Young ,
A. Carlsson ,
B. Olausson ,
A. Nordenhem ,
B. Paulsson  and
M. Brecher
S. McElroy
Affiliation:
University of Cincinnati College of Medicine, Cincinnati, OH, USA
A.H. Young
Affiliation:
Department of Psychiatry, Institute of Mental Health, The University of British Columbia, Vancouver, BC, Canada
A. Carlsson
Affiliation:
AstraZeneca, Sodertalje, Sweden
B. Olausson
Affiliation:
AstraZeneca, Sodertalje, Sweden
A. Nordenhem
Affiliation:
AstraZeneca, Sodertalje, Sweden
B. Paulsson
Affiliation:
AstraZeneca, Sodertalje, Sweden
M. Brecher
Affiliation:
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

Evaluate efficacy and tolerability of quetiapine and paroxetine monotherapy for major depressive episodes in bipolar disorder during an acute 8-week period and up to 52-week continuation phase.

Methods:

740 patients (478 bipolar I, 262 bipolar II) were randomized to quetiapine 300mg/d (n=245), quetiapine 600mg/d (n=247), paroxetine 20mg/d (n=122), or placebo (n=126) for 8 weeks. Primary endpoint was change from baseline to 8 weeks in MADRS total score. After 8 weeks, patients with MADRS ≤12 and YMRS ≤12 entered a 26- to 52-week continuation phase of quetiapine (300mg/d or 600mg/d) or placebo. Patients on paroxetine received 300mg/d of quetiapine (continuation phase results not included here and to be presented separately).

Results:

LSM MADRS score change at 8 weeks was -16.19 (quetiapine 300mg/d),-16.31 (quetiapine 600mg/d), -13.76 (paroxetine), and -12.60 (placebo; P<0.001 for both quetiapine doses, P=0.313 for paroxetine, versus placebo; LOCF ANCOVA). Quetiapine (both doses)-treated patients showed significantly greater improvements (P≤0.05) in MADRS response rate, HAM-D, CGI-BP-S, CGI-BP-Change, HAM-A, and MADRS item 10 (suicidal thoughts) at Week 8 versus placebo; MADRS remission rates improved with quetiapine 600mg/d versus placebo (P=0.012). Paroxetine improved HAM-A scores versus placebo (P=0.033).

Most common adverse events considered drug-related included dry mouth, somnolence, sedation, and dizziness with quetiapine (both doses); dry mouth, sedation, headache, insomnia, and nausea with paroxetine.

Conclusions:

Quetiapine (300mg/d or 600mg/d) was more effective than placebo for the treatment of acute depressive episodes in bipolar I and II disorder. Quetiapine treatment was generally well tolerated.

Supported by funding from AstraZeneca Pharmaceuticals LP.

Type
Poster Session II: Bipolar Disorders
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S239
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.